Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Analyst Sharon di Stefano calls two upcoming trials of Medgenics' (MDGN -3%) Infraddure Biopump...

  • Thursday, August 30, 2012, 9:52 AM ET
    Analyst Sharon di Stefano calls two upcoming trials of Medgenics' (MDGN -3%) Infraddure Biopump for treating hepatitis C as "a leap forward for viral medicine no less important than the first studies in HIV decades ago." And with the recent failure of a Bristol-Myers treatment in clinical trials, the timing is good. Still, with a number of rival drugs being trialled, one wonders whether di Stefano is guilty of hyperbole.
Track new comments on this story

This news story has 3 comments:

  •  
    I wonder why Stephen McMurray, one of Medgenics' directors sold 10,935 shares at $12.50 each on 24 August 2012, without explanation in the news release.
    30 Aug 2012, 04:04 PM Reply Like
  •  
    maybe he just needed some money ? it happens to all of us...
    what is his total holding ?
    3 Sep 2012, 08:18 AM Reply Like
  •  
    there is a mention of it on RNS from 28/8/12
    4 Sep 2012, 04:28 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »